2023
Black-White differences in uterine cancer symptomatology and stage at diagnosis
Xu X, Chen L, Nunez-Smith M, Clark M, Ferris J, Hershman D, Wright J. Black-White differences in uterine cancer symptomatology and stage at diagnosis. Gynecologic Oncology 2023, 180: 118-125. PMID: 38091770, PMCID: PMC10922746, DOI: 10.1016/j.ygyno.2023.11.029.Peer-Reviewed Original ResearchAdvanced stage diagnosisWhite patientsPostmenopausal bleedingPatient characteristicsEnd Results-Medicare databaseBlack-white differencesBlack-White disparitiesBlack patientsUterine cancerCancer symptomsHigh riskPatientsAdvanced stageSymptomsDiagnosisCancer symptomatologyRegression modelsRiskLarge proportionBleedingHistologyCancerEpidemiologySymptomatologyMonthsHyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer
Gelissen J, Adjei N, McNamara B, Mutlu L, Harold J, Clark M, Altwerger G, Dottino P, Huang G, Santin A, Azodi M, Ratner E, Schwartz P, Andikyan V. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer. Annals Of Surgical Oncology 2023, 30: 5597-5609. PMID: 37358686, DOI: 10.1245/s10434-023-13757-0.Peer-Reviewed Original ResearchConceptsHyperthermic intraperitoneal chemotherapyIntraperitoneal chemotherapyOvarian cancerStage III epithelial ovarian cancerUse of HIPECEpithelial ovarian cancerHigh-quality evidenceOvarian cancer treatmentHIPEC useInterval cytoreductionCytoreductive surgeryNeoadjuvant chemotherapyPerioperative careHIPEC protocolsHIPEC techniqueTreatment modalitiesPatient outcomesSingle administrationTumor disseminationChemotherapyCancerCancer treatmentOptimal candidatesMain siteLife dataRacial disparities in diagnostic evaluation of uterine cancer among Medicaid beneficiaries
Xu X, Chen L, Nunez-Smith M, Clark M, Wright J. Racial disparities in diagnostic evaluation of uterine cancer among Medicaid beneficiaries. Journal Of The National Cancer Institute 2023, 115: 636-643. PMID: 36788453, PMCID: PMC10248843, DOI: 10.1093/jnci/djad027.Peer-Reviewed Original ResearchConceptsAbnormal uterine bleedingWhite patientsUterine cancerFirst diagnostic procedureDiagnostic evaluationBlack patientsDiagnostic proceduresBlack-White disparitiesManagement visitsMarketScan Multi-State Medicaid DatabaseMulti-State Medicaid DatabaseUterine bleedingPatient characteristicsMedicaid databaseEarly diagnosisMedicaid beneficiariesMultivariable regressionPatientsCancerRacial disparitiesDiagnosisVisitsMore evaluationDisparitiesBleeding
2019
Resuming chemotherapy after interval cytoreductive surgery in ovarian cancer: The impact of time and temperature
Clark M, Kollara A, May T, Brown T. Resuming chemotherapy after interval cytoreductive surgery in ovarian cancer: The impact of time and temperature. Gynecologic Oncology 2019, 154: 55-56. DOI: 10.1016/j.ygyno.2019.04.133.Peer-Reviewed Original ResearchIs there a benefit to the lowest possible CA-125: The relationship between biomarkers and survival in epithelial ovarian cancer
Clark M, Al houssan L, Liu Z, Bernardini M. Is there a benefit to the lowest possible CA-125: The relationship between biomarkers and survival in epithelial ovarian cancer. Gynecologic Oncology 2019, 154: 261. DOI: 10.1016/j.ygyno.2019.04.603.Peer-Reviewed Original ResearchLimitations in Correspondence Programs for Cervical Cancer Screening: Who Are the Women We Are Missing?
Clark M, Lee A, Kupets R. Limitations in Correspondence Programs for Cervical Cancer Screening: Who Are the Women We Are Missing? Journal Of Obstetrics And Gynaecology Canada 2019, 41: 1410-1415. PMID: 30803876, DOI: 10.1016/j.jogc.2018.11.034.Peer-Reviewed Original ResearchConceptsPrimary care physiciansCare physiciansHealth care encountersCervical cancerCare encountersMore health care encountersRetrospective observational studyCervical cancer screeningHealth care servicesBasis of ageEligible womenCancer screeningAdministrative databasesObservational studyScreening programCare servicesHealth servicesPhysiciansCorrespondence programWomenFurther riskOutreach methodsCancerMailingInfrequent users
2018
Investigating the time intervals between primary cytoreductive surgery and initiation of adjuvant chemotherapy in patients with advanced epithelial ovarian cancer who had optimal cytoreduction surgery with bowel resection
Lee Y, Lee J, Paik E, Clark M, Kim R, Brown T, May T. Investigating the time intervals between primary cytoreductive surgery and initiation of adjuvant chemotherapy in patients with advanced epithelial ovarian cancer who had optimal cytoreduction surgery with bowel resection. Gynecologic Oncology 2018, 149: 98. DOI: 10.1016/j.ygyno.2018.04.226.Peer-Reviewed Original ResearchDoes the time interval off neoadjuvant chemotherapy before and after interval debulking surgery affect the overall survival of women with advanced-epithelial ovarian cancer?
Clark M, Lee Y, Xu W, Brown T, May T. Does the time interval off neoadjuvant chemotherapy before and after interval debulking surgery affect the overall survival of women with advanced-epithelial ovarian cancer? Gynecologic Oncology 2018, 149: 92. DOI: 10.1016/j.ygyno.2018.04.210.Peer-Reviewed Original Research
2017
563 Robatic Tumor Debulking with Partial Cystectomy, Bladder Reconstruction, and Ureteral Implantation in Recurrent Endometrial Cancer
Seifi F, Davis M, Clark M, Paraiso E, Azodi M. 563 Robatic Tumor Debulking with Partial Cystectomy, Bladder Reconstruction, and Ureteral Implantation in Recurrent Endometrial Cancer. Journal Of Minimally Invasive Gynecology 2017, 24: s184-s185. DOI: 10.1016/j.jmig.2017.08.591.Peer-Reviewed Original Research
2016
Novel targeted therapies in uterine serous carcinoma, an aggressive variant of endometrial cancer.
Menderes G, Clark M, Santin AD. Novel targeted therapies in uterine serous carcinoma, an aggressive variant of endometrial cancer. Discovery Medicine 2016, 21: 293-303. PMID: 27232515.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, MonoclonalAntineoplastic AgentsClass I Phosphatidylinositol 3-KinasesCyclin ECystadenocarcinoma, SerousEndometrial NeoplasmsEpothilonesExomeFemaleHumansMolecular Targeted TherapyMutationNeoplasm Recurrence, LocalOncogene ProteinsPrognosisProtein Kinase InhibitorsProtein Phosphatase 2RadioimmunotherapyReceptor, ErbB-2Sequence Analysis, DNASignal TransductionTOR Serine-Threonine KinasesTubulin ModulatorsTumor Suppressor Protein p53Uterine NeoplasmsVascular Endothelial Growth Factor AConceptsUterine serous carcinomaEndometrial cancerSerous carcinomaTreatment of USCPIK3CA/AKT/mTOREndometrial cancer casesRecent whole-exome sequencing studiesHER2/neu geneNovel therapeutic targetAkt/mTORBiologic therapyAggressive variantDismal prognosisAggressive subtypeWhole-exome sequencing studiesCancer casesTherapeutic targetSubsequent deathDriver mutationsNeu geneGain of functionCarcinomaTherapyCancerSequencing studies